



Figure S3 - Kaplan-Meier plots of probability of overall survival in patients with advanced PDAC receiving first-line FOLFIRINOX (A) or nab-paclitaxel/gemcitabine (B) or patients with GC/EGJC receiving an oxaliplatin-containing regimen (C). A) The median OS in the Increased Benefit cohort is 10.1 months (90%) longer than the median OS in the Decreased Benefit cohort (HR = 0.478, 95% CI: 0.289-0.792, log-rank $p = 0.003$). B) The median OS in the Increased Benefit cohort is one month (11%) longer than the median OS in the Decreased Benefit cohort (HR = 0.958, 95% CI: 0.658-1.395, log-rank $p = 0.823$). C) The median OS in the Increased Benefit cohort is 5.1 months (58%) longer than the median OS in the Decreased Benefit cohort (HR = 0.437, 95% CI: 0.250-0.763, log-rank $p = 0.003$).